Literature DB >> 19090505

St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial.

Jerome Sarris1, David J Kavanagh, Gary Deed, Kerry M Bone.   

Abstract

OBJECTIVE: We report the first randomised controlled trial (RCT) using a combination of St. John's wort (SJW) and Kava for the treatment of major depressive disorder (MDD) with comorbid anxiety.
METHODS: Twenty-eight adults with MDD and co-occurring anxiety were recruited for a double-blind RCT. After a placebo run-in of 2 weeks, the trial had a crossover design testing SJW and Kava against placebo over two controlled phases, each of 4 weeks. The primary analyses used intention-to-treat and completer analyses.
RESULTS: On both intention-to-treat (p = 0.047) and completer analyses (p = 0.003), SJW and Kava gave a significantly greater reduction in self-reported depression on the Beck Depression Inventory (BDI-II) over placebo in the first controlled phase. However, in the crossover phase, a replication of those effects in the delayed medication group did not occur. Nor were there significant effects on anxiety or quality of life.
CONCLUSION: There was some evidence of antidepressant effects using SJW and Kava in a small sample with comorbid anxiety. Possible explanations for the absence of anxiolysis may include a potential interaction with SJW, the presence of depression, or an inadequate dose of Kava.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19090505     DOI: 10.1002/hup.994

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

Review 1.  Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review.

Authors:  Shaheen E Lakhan; Karen F Vieira
Journal:  Nutr J       Date:  2010-10-07       Impact factor: 3.271

2.  The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.

Authors:  J Sarris; D J Kavanagh; G Byrne; K M Bone; J Adams; G Deed
Journal:  Psychopharmacology (Berl)       Date:  2009-05-09       Impact factor: 4.530

3.  A Combination of Essential Fatty Acids, Panax Ginseng Extract, and Green Tea Catechins Modifies Brain fMRI Signals in Healthy Older Adults.

Authors:  O T Carmichael; S Pillai; P Shankapal; A McLellan; D G Kay; B T Gold; J N Keller
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

Review 4.  Dietary and botanical anxiolytics.

Authors:  Elham Alramadhan; Mirna S Hanna; Mena S Hanna; Todd A Goldstein; Samantha M Avila; Benjamin S Weeks
Journal:  Med Sci Monit       Date:  2012-04

5.  Neuroprotective properties of kavalactones.

Authors:  Yew-Min Tzeng; Meng-Jen Lee
Journal:  Neural Regen Res       Date:  2015-06       Impact factor: 5.135

6.  Flavokawains a and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice.

Authors:  Sreekanth C Narayanapillai; Pablo Leitzman; M Gerard O'Sullivan; Chengguo Xing
Journal:  Chem Res Toxicol       Date:  2014-09-12       Impact factor: 3.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.